Newsletter Subject

Empower Clinics (CSE:CBDT) Subsidiary Medisure Launches First Health Canada Approved At-Home Vitamin D Testing Kit

From

stockhouse.com

Email Address

newsblast@stockhouse.com

Sent On

Mon, Apr 25, 2022 05:26 PM

Email Preheader Text

Pre-launch orders secured via online and pharmacies including PharmaChoice with 800 stores ‌ â

Pre-launch orders secured via online and pharmacies including PharmaChoice with 800 stores ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ [Open in your browser]( NEWS BLAST [Logo] --------------------------------------------------------------- Press Release - Empower Clinics Subsidiary Medisure Launches First Health Canada Approved At-Home Vitamin D Testing Kit Pre-launch orders secured via online and pharmacies including PharmaChoice with 800 stores VANCOUVER, BC / April 25, 2022 / EMPOWER CLINICS INC ([CSE:CBDT]( ("Empower" or the "Company") an integrated healthcare company - serving patients through medical centers, telemedicine platforms, a medical device company, and a high complexity medical diagnostics laboratory - announced the launch of another innovative at-home testing solution: Vitamin D Rapid Testing Kit within its Medisure brand. "The launch and pre-sales of this Vitamin D at-home testing solution is a perfect execution of our vision of being a leading integrated healthcare company," stated Steven McAuley, Chairman and CEO of Empower Clinics. "We co-created this product in partnership with pharmacies who in-turn placed advance orders. We maximized internal synergies by distributing this Medisure product to our The Medi-Collective (TMC) clinics. And we are delivering on our commitment to continually offer convenient, accessible and integrated healthcare solutions - online, in our TMC clinics or in our partner pharmacies - to patients across Canada." Studies have shown disturbing evidence of widespread vitamin D deficiency in many population groups, particularly within nations at high latitude with limited sunlight like Canada. Numerous recent studies in the scientific literature associate vitamin D deficiency with a colossal increase in morbidity and mortality. "Many Canadians suffer from high levels of Vitamin D deficiency. It's a well-known and strong underlying contributor to many other medical conditions. That's why I am so proud of the MediSure team for being a Canadian first to launch a Health Canada Licensed at-home Vitamin D Rapid Testing Kit," stated Mario Cortis, President of MediSure. "Canadians can now conveniently, accurately and quickly test their own Vitamin D levels at home and then plan a strategy with their pharmacist to increase their Vitamin D levels." The MediSure® Vitamin D Rapid Test Kits will be available at local PharmaChoice® pharmacies across the country beginning in May 2022. PharmaChoice is Canada's fastest growing pharmacy with more than 800 stores. "We are excited that Vitamin D self-testing is finally available for patients," said Curtis Chafe, Director of Pharmacy Services at PharmaChoice. "Using this tool will help many Canadians identify vitamin D deficiency, and with guidance from our pharmacists, they can receive treatment efficiently and safely." The product will also be available for sale at [www.medisure.ca]( throughout The Medi-Collective clinics and at participating pharmacies in Canada. This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management [( ABOUT EMPOWER: Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, a medical device company and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders. ON BEHALF OF THE BOARD OF DIRECTORS: Steven McAuley Chief Executive Officer CONTACTS: Media: Steven McAuley CEO s.mcauley@empowerclinics.com 604-227-0865 Investors: Tamara Mason Business Development & Communications t.mason@empowerclinics.com 604-359-9107 DISCLAIMER FOR FORWARD-LOOKING STATEMENTS This news release contains certain "forward-looking statements" or "forward-looking information" (collectively "forward looking statements") within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as "plans", "continues", "expects", "projects", "intends", "believes", "anticipates", "estimates", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include statements regarding: Such forward-looking statements are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that risks related to supply chains and access to labour; that legislative changes may have an adverse effect on the Company's business and product development; that general business, economic, competitive, political and social uncertainties; and other factors beyond the Company's control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur on the terms or in the time expected, or at all, or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws. SOURCE: Empower Clinics Inc. Click here to visit the [Empower Clinics Inc]( website --------------------------------------------------------------- The Information in a Stockhouse Publishing Ltd. Stockhouse News Blast is A PAID ADVERTISEMENT and is for the viewers information only. Empower Clinics Inc has paid a fee not exceeding $3500.00 in cash to have their corporate information featured. The corporate information is purely and solely the responsibility of Empower Clinics Inc and it is neither commented upon, researched, or in any manner the responsibility of Stockhouse Publishing Ltd., whose only function is as a supplier of media facilities. Any information provided by the advertisers of Stockhouse Publishing Ltd., through its media services, is not to be construed as a recommendation or suggestion or offer to buy or sell securities, but is provided purely as an informational media service. Stockhouse Publishing Ltd. makes no warranties or undertakings as to the accuracy or completeness of this information. All due diligence should be done by the reader or their financial advisor. Investing in securities is speculative and carries risk. Persons who wish to buy or sell securities should only do so in consultation with their registered securities advisers. --------------------------------------------------------------- [facebook]( [twitter]( [LinkedIn]( [stockhouse]( Stockhouse Publishing Ltd. | 1100 – 609 West Hastings Street | Vancouver | BC | V6B 4W4 | CA This email was sent to you by Stockhouse Publishing Ltd. because you consented to receive messages from us. You may [manage your subscription]( preferences at any time. You may contact our email compliance officer at compliance@stockhouse.com

Marketing emails from stockhouse.com

View More
Sent On

07/06/2024

Sent On

07/06/2024

Sent On

06/06/2024

Sent On

04/06/2024

Sent On

03/06/2024

Sent On

31/05/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.